Journal of Neuro-Oncology

, Volume 140, Issue 2, pp 281–288 | Cite as

Long non-coding RNA MEG3 regulates proliferation, apoptosis, and autophagy and is associated with prognosis in glioma

  • Haikang Zhao
  • Xin Wang
  • Xiaoyun Feng
  • Xiaoqiang Li
  • Li Pan
  • Jianrong Liu
  • Fenglu Wang
  • Zhihai Yuan
  • Lei Yang
  • Jun Yu
  • Rujuan SuEmail author
  • Yuelin ZhangEmail author
  • Lianting MaEmail author
Clinical Study



Accumulating evidence indicates that dysregulated long noncoding RNAs (lncRNAs) play critical roles in tumorigenesis and cancer progression. LncRNA-maternally expressed gene 3 (MEG3) has been shown to be involved in the initiation and development of several cancers, including glioma. However, the clinical prognostic value of MEG3 in glioma has not yet been fully elucidated.


The expression levels of MEG3 were detected in 79 glioma tissues and adjacent normal brain tissues, as well as, glioma cells and normal human astrocytes by qRT-PCR. Kaplan–Meier and Cox regression methods were utilized for the survival analysis. MTT assay, flow cytometry, and immunofluorescence assay were carried out to detect the impact of MEG3 on glioma cell proliferation, apoptosis, and autophagy.


The current results showed that MEG3 expression was significantly downregulated in glioma tissues and cell line and negatively correlated with WHO grade in glioma patients. Low MEG3 expression was significantly associated with the advanced WHO grade, low Karnofsky performance score (KPS), IDH wild-type, and tumor recurrence. Patients displaying a low expression of MEG3 contributed to poor overall survival. The downregulated level of MEG3, advanced WHO grade, low KPS, IDH wild-type, and tumor recurrence were independent poor prognostic indicators in glioma patients. The in vitro experiments demonstrated that the MEG3 overexpression remarkably suppressed the proliferation while facilitating apoptosis and autophagy in glioma cells.


These findings indicated a critical role of MEG3 in glioma cell proliferation, apoptosis, and autophagy. Also, the gene was found to be significantly associated with the prognosis in glioma patients. Thus, it might provide a new target for predicting prognosis and therapeutic intervention in glioma.


LncRNAs MEG3 Proliferation Apoptosis Autophagy Prognosis Glioma 



We thank Professor Li for assistance in language editing.


This work was supported by the National Natural Science Funds (No. 81470438) and Fund for the Development of Key Subjects from Xi’an Medical University.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Ethics approval

The study was approved by the Research Ethics Committee of Wuhan General Hospital of PLA, and it complied with the Declaration of Helsinki. All procedures performed in this study were in accordance with the 1964 Helsinki Declaration and its later amendments.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Colquhoun A (2017) Cell biology-metabolic crosstalk in glioma. Int J Biochem Cell Biol 89:171–181CrossRefGoogle Scholar
  2. 2.
    Bugiani M, Veldhuijzen VZS, Caretti V et al (2017) Deceptive morphologic and epigenetic heterogeneity in diffuse intrinsic pontine glioma. Oncotarget 8(36):60447–60452CrossRefGoogle Scholar
  3. 3.
    Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109CrossRefGoogle Scholar
  4. 4.
    Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466CrossRefGoogle Scholar
  5. 5.
    Sasaki H, Yoshida K (2017) Treatment recommendations for adult patients with diffuse gliomas of grades II and III according to the new WHO classification in 2016. Neurol Med Chir (Tokyo) 57:658–666CrossRefGoogle Scholar
  6. 6.
    Koch L (2017) Functional genomics: screening for lncRNA function. Nat Rev Genet 18(2):70Google Scholar
  7. 7.
    Li J, Meng H, Bai Y et al (2016) Regulation of lncRNA and its role in cancer metastasis. Oncol Res 23(5):205–217CrossRefGoogle Scholar
  8. 8.
    Shi J, Dong B, Cao J et al (2017) Long non-coding RNA in glioma: signaling pathways. Oncotarget 8(16):27582–27592CrossRefGoogle Scholar
  9. 9.
    Jandura A, Krause HM (2017) The new RNA world: growing evidence for long noncoding RNA functionality. Trends Genet 33(10):665–676CrossRefGoogle Scholar
  10. 10.
    Wang R, Li Y, Zhu G et al (2017) Long noncoding RNA CASC2 predicts the prognosis of glioma patients and functions as a suppressor for gliomas by suppressing Wnt/beta-catenin signaling pathway. Neuropsychiatr Dis Treat 13:1805–1813CrossRefGoogle Scholar
  11. 11.
    Alvarez-Dominguez JR, Lodish HF (2017) Emerging mechanisms of long noncoding RNA function during normal and malignant hematopoiesis. Blood 130:1965–1975CrossRefGoogle Scholar
  12. 12.
    Kiang KM, Zhang XQ, Leung GK (2015) Long non-coding RNAs: the key players in glioma pathogenesis. Cancers (Basel) 7(3):1406–1424CrossRefGoogle Scholar
  13. 13.
    Wu F, Zhang C, Cai J et al (2017) Upregulation of long noncoding RNA HOXA-AS3 promotes tumor progression and predicts poor prognosis in glioma. Oncotarget 8(32):53110–53123Google Scholar
  14. 14.
    Ma KX, Wang HJ, Li XR et al (2015) Long noncoding RNA MALAT1 associates with the malignant status and poor prognosis in glioma. Tumour Biol 36(5):3355–3359CrossRefGoogle Scholar
  15. 15.
    Hu L, Lv QL, Chen SH et al (2016) Up-regulation of long non-coding RNA AB073614 predicts a poor prognosis in patients with glioma. Int J Environ Res Public Health 13(4):433CrossRefGoogle Scholar
  16. 16.
    Zhao W, Sun C, Cui Z (2017) A long noncoding RNA UCA1 promotes proliferation and predicts poor prognosis in glioma. Clin Transl Oncol 19(6):735–741CrossRefGoogle Scholar
  17. 17.
    Balik V, Srovnal J, Sulla I et al (2013) MEG3: a novel long noncoding potentially tumour-suppressing RNA in meningiomas. J Neurooncol 112(1):1–8CrossRefGoogle Scholar
  18. 18.
    Zhou C, Huang C, Wang J et al (2017) LncRNA MEG3 downregulation mediated by DNMT3b contributes to nickel malignant transformation of human bronchial epithelial cells via modulating PHLPP1 transcription and HIF-1alpha translation. Oncogene 36(27):3878–3889CrossRefGoogle Scholar
  19. 19.
    Cui X, Jing X, Long C et al (2017) Long noncoding RNA MEG3, a potential novel biomarker to predict the clinical outcome of cancer patients: a meta-analysis. Oncotarget 8(12):19049–19056CrossRefGoogle Scholar
  20. 20.
    Luo G, Wang M, Wu X et al (2015) Long non-coding RNA MEG3 inhibits cell proliferation and induces apoptosis in prostate cancer. Cell Physiol Biochem 37(6):2209–2220CrossRefGoogle Scholar
  21. 21.
    Ma B, Gao Z, Lou J et al (2017) Long noncoding RNA MEG3 contributes to cisplatin-induced apoptosis via inhibition of autophagy in human glioma cells. Mol Med Rep 16(3):2946–2952CrossRefGoogle Scholar
  22. 22.
    Mercer TR, Dinger ME, Mattick JS (2009) Long non-coding RNAs: insights into functions. Nat Rev Genet 10(3):155–159CrossRefGoogle Scholar
  23. 23.
    Kondo Y, Shinjo K, Katsushima K (2017) Long non-coding RNAs as an epigenetic regulator in human cancers. Cancer Sci 108(10):1927–1933CrossRefGoogle Scholar
  24. 24.
    Kong X, Liu W, Kong Y (2017) Roles and expression profiles of long non-coding RNAs in triple-negative breast cancers. J Cell Mol Med 22:390–394CrossRefGoogle Scholar
  25. 25.
    Fan C, Tang Y, Wang J et al (2017) Role of long non-coding RNAs in glucose metabolism in cancer. Mol Cancer 16(1):130CrossRefGoogle Scholar
  26. 26.
    Yang L, Wang H, Shen Q et al (2017) Long non-coding RNAs involved in autophagy regulation. Cell Death Dis 8(10):e3073CrossRefGoogle Scholar
  27. 27.
    Vafaee F, Colvin EK, Mok SC et al (2017) Functional prediction of long non-coding RNAs in ovarian cancer-associated fibroblasts indicate a potential role in metastasis. Sci Rep 7(1):10374CrossRefGoogle Scholar
  28. 28.
    Sun CC, Li SJ, Li G et al (2016) Long intergenic noncoding RNA 00511 acts as an oncogene in non-small-cell lung cancer by binding to EZH2 and suppressing p57. Mol Ther Nucleic Acids 5(11):e385CrossRefGoogle Scholar
  29. 29.
    Liu Y, Qian J, Li X et al (2016) Long noncoding RNA BX357664 regulates cell proliferation and epithelial-to-mesenchymal transition via inhibition of TGF-beta1/p38/HSP27 signaling in renal cell carcinoma. Oncotarget 7(49):81410–81422Google Scholar
  30. 30.
    Kang CM, Hu YW, Nie Y et al (2016) Long non-coding RNA RP5-833A20.1 inhibits proliferation, metastasis and cell cycle progression by suppressing the expression of NFIA in U251 cells. Mol Med Rep 14(6):5288–5296CrossRefGoogle Scholar
  31. 31.
    Liu Z, Wu C, Xie N et al (2017) Long non-coding RNA MEG3 inhibits the proliferation and metastasis of oral squamous cell carcinoma by regulating the WNT/beta-catenin signaling pathway. Oncol Lett 14(4):4053–4058CrossRefGoogle Scholar
  32. 32.
    Zhang J, Yao T, Wang Y et al (2016) Long noncoding RNA MEG3 is downregulated in cervical cancer and affects cell proliferation and apoptosis by regulating miR-21. Cancer Biol Ther 17(1):104–113CrossRefGoogle Scholar
  33. 33.
    Sun L, Li Y, Yang B (2016) Downregulated long non-coding RNA MEG3 in breast cancer regulates proliferation, migration and invasion by depending on p53’s transcriptional activity. Biochem Biophys Res Commun 478(1):323–329CrossRefGoogle Scholar
  34. 34.
    Gu L, Zhang J, Shi M et al (2017) lncRNA MEG3 had anti-cancer effects to suppress pancreatic cancer activity. Biomed Pharmacother 89:1269–1276CrossRefGoogle Scholar
  35. 35.
    Zhang L, Liang X, Li Y (2017) Long non-coding RNA MEG3 inhibits cell growth of gliomas by targeting miR-93 and inactivating PI3K/AKT pathway. Oncol Rep 38(4):2408–2416CrossRefGoogle Scholar
  36. 36.
    Zhang CY, Yu MS, Li X et al (2017) Overexpression of long non-coding RNA MEG3 suppresses breast cancer cell proliferation, invasion, and angiogenesis through AKT pathway. Tumour Biol 39(6):1393388353Google Scholar
  37. 37.
    Xiu YL, Sun KX, Chen X et al (2017) Upregulation of the lncRNA Meg3 induces autophagy to inhibit tumorigenesis and progression of epithelial ovarian carcinoma by regulating activity of ATG3. Oncotarget 8(19):31714–31725CrossRefGoogle Scholar
  38. 38.
    Tong GF, Qin N, Sun LW et al (2017) Long noncoding RNA MEG3 suppresses glioma cell proliferation, migration, and invasion by acting as competing endogenous RNA of MiR-19a. Oncol Res 25:1471–1478CrossRefGoogle Scholar
  39. 39.
    Gong X, Huang M (2017) Long non-coding RNA MEG3 promotes the proliferation of glioma cells through targeting Wnt/beta-catenin signal pathway. Cancer Gene Ther 24(9):381–385CrossRefGoogle Scholar
  40. 40.
    Tian ZZ, Guo XJ, Zhao YM et al (2015) Decreased expression of long non-coding RNA MEG3 acts as a potential predictor biomarker in progression and poor prognosis of osteosarcoma. Int J Clin Exp Pathol 8(11):15138–15142Google Scholar
  41. 41.
    Yin DD, Liu ZJ, Zhang E et al (2015) Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Tumour Biol 36(6):4851–4859CrossRefGoogle Scholar
  42. 42.
    Zhang Z, Liu T, Wang K et al (2017) Down-regulation of long non-coding RNA MEG3 indicates an unfavorable prognosis in non-small cell lung cancer: evidence from the GEO database. Gene 630:49–58CrossRefGoogle Scholar
  43. 43.
    Zhang J, Lin Z, Gao Y et al (2017) Downregulation of long noncoding RNA MEG3 is associated with poor prognosis and promoter hypermethylation in cervical cancer. J Exp Clin Cancer Res 36(1):5CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of NeurosurgeryWuhan General Hospital of PLAWuhanChina
  2. 2.Department of Neurosurgery, The Second Affiliated HospitalXi’an Medical UniversityXi’anChina
  3. 3.Department of Neurosurgery, Tangdu HospitalFourth Military Medical UniversityXi’anChina
  4. 4.Experimental Center, The Second Affiliated HospitalXi’an Medical UniversityXi’anChina
  5. 5.Department of OncologyFirst Affiliated Hospital of Medical College of Xi’an Jiaotong UniversityXi’anChina
  6. 6.Shaanxi Key Laboratory of Preventinon and Therapy of Cerebral DiseaseXi’an Medical UniversityXi’anChina

Personalised recommendations